(S)-N-(3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide | 1062671-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-N-(3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide
• 英文别名: N-((S)-3-{4-[3-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide；N-[(2S)-3-[4-[3-[2-(diethylamino)-6-methylpyridin-4-yl]-1,2,4-oxadiazol-5-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
• CAS: 1062671-18-4
• 化学式: C₂₆H₃₅N₅O₅
• 分子量: 497.594
• InChiKey: CWMADWDSWMWWAD-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  tert-butyl 2-chloro-6-(diethylamino)isonicotinate 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 盐酸羟胺 、 potassium tert-butylate 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氨 、 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 75.42h， 生成 (S)-N-(3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide
  参考文献：
  名称：

  Novel S1P₁ Receptor Agonists − Part 3: From Thiophenes to Pyridines

  摘要：

  In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P(1) agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P(1) agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P(1) agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P(1), and S1P(3) receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

  DOI：

  10.1021/jm4014696

文献信息

• AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
  申请人：Bolli Martin

  公开号：US20100087417A1

  公开（公告）日：2010-04-08

  The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及新型氨基吡啶衍生物，其制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2125797A1

  公开（公告）日：2009-12-02
• US8592460B2
  申请人：——

  公开号：US8592460B2

  公开（公告）日：2013-11-26
• [EN] AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'AMINO-PYRIDINE COMME AGONISTES DU RÉCEPTEUR S1P1/EDG1
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2008114157A1

  公开（公告）日：2008-09-25

  [EN] The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
  [FR] L'invention porte sur de nouveaux dérivés d'amino-pyridine, sur leur préparation et sur leur utilisation comme composés pharmaceutiquement actifs. Lesdits composés agissent en particulier comme agents immunomodulateurs.
• Novel S1P₁ Receptor Agonists − Part 3: From Thiophenes to Pyridines
  作者：Martin H. Bolli、Stefan Abele、Magdalena Birker、Roberto Bravo、Daniel Bur、Ruben de Kanter、Christopher Kohl、Julien Grimont、Patrick Hess、Cyrille Lescop、Boris Mathys、Claus Müller、Oliver Nayler、Markus Rey、Michael Scherz、Gunther Schmidt、Jürgen Seifert、Beat Steiner、Jörg Velker、Thomas Weller

  DOI：10.1021/jm4014696

  日期：2014.1.9

  In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P(1) agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P(1) agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P(1) agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P(1), and S1P(3) receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.